×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Financial Markets | Infrastructure | Money | GSK anemia drug

GSK Says Anemia Drug Shows Positive Safety Profile

GSK
View of a GlaxoSmithKline (GSK) Shanghai, China, manufacturing plant. (AP)

Friday, 05 November 2021 01:39 PM

GlaxoSmithKline said its anemia pill for patients with kidney disease was shown to have about the same side effect risk as the current standard treatment in two important patient groups, a key advantage in a tight race with rival drug developers.

GSK said on Friday that risk measures to determine whether its drug did not pose a higher risk than versions of the current treatment known as Epo, came in better than the predefined hurdle in two trials treating patients on dialysis and those not yet on dialysis.

In the trials, its drug daprodustat also improved or maintained hemoglobin levels, when compared to the standard of care, the company added.

Analysts have said that safety from side effects such as heart attack or stroke will be a crucial factor to differentiate daprodustat, which GSK has said could have annual sales of as much as 1 billion pounds ($1.35 billion), from competing pills under development by AstraZeneca and others.

Anemia is characterized by a low count of red blood cells or lack of the oxygen-carrying protein hemoglobin in those cells. Patients with kidney disease - ever growing in number due to a rise in obesity, diabetes and high blood pressure - suffer increasingly from anemia as renal function declines.

In later disease stages, particularly when depending on blood-cleansing dialysis, patients currently receive injections of a synthetic version of hormone erythropoietin, or Epo, to stimulate red-blood cell production. But the treatment raises the risk of dangerous heart attacks and strokes.

The new class of more convenient oral drugs, known as HIF-PH inhibitors, has attracted several competing drugmakers.

AstraZeneca and Fibrogen in August suffered a major setback with their drug roxadustat, part of the same HIF-PH category, when the U.S. Food and Drug Administration (FDA) in August declined approval, citing the need for an additional clinical study on safety.

Another HIF-PH inhibitor, vadadustat by Akebia and its Japanese partner Otsuka Pharmaceutical, has been under review by the U.S. FDA since June.

GSK's daprodustat is only cleared for use in Japan and GSK said it would make requests for approval with other regulators worldwide, underpinned by the new data. The company had published a short summary of the positive results in June.

The positive results come as a boost for GSK boss Emma Walmsley, whose strategy to separately list its consumer health unit has been criticized by activist investor Elliott. Daprodustat is one of a group of GSK drug candidates in late stages of development where the company sees potential for annual peak sales of more than 20 billion pounds. ($1 = 0.7428 pounds) (Reporting by Yadarisa Shabong, Sachin Ravikumar and Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich, Louise Heavens, Elaine Hardcastle)

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
GlaxoSmithKline said its anemia pill for patients with kidney disease was shown to have about the same side effect risk as the current standard treatment in two important patient groups, a key advantage in a tight race with rival drug developers.
GSK anemia drug
449
2021-39-05
Friday, 05 November 2021 01:39 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved